Shijiazhuang Yiling Pharmaceutical Co Ltd SZSE:002603:
SAYS Q3 NET PROFIT UP 1264.6% Y/Y
Yiling Pharmaceutical Q3 Net Profit Up 1264.6% Y/Y
Shijiazhuang Yiling Pharmaceutical Co., Ltd. on 6ix
Earlier from Shijiazhuang Yiling Pharmaceutical
- Shijiazhuang Yiling Pharmaceutical Co: Net profit rose 26% to ¥669 million despite a 12% revenue drop, with strong cash flow
- Shijiazhuang Yiling Pharmaceutical Co: Net profit grew 7.25% year-over-year in Q1 2025 despite a 6.52% revenue drop
- Shijiazhuang Yiling Pharmaceutical Co: 2024 net loss driven by sales drop, inventory write-downs, and high R&D; cost control prioritized
- Shijiazhuang Yiling Pharmaceutical Co: Revenue and profit declined sharply year-over-year, but operating cash flow improved
- Shijiazhuang Yiling Pharmaceutical Co: Revenue and profit declined sharply, but R&D and market leadership in core products remain strong
Later from Shijiazhuang Yiling Pharmaceutical
- Shijiazhuang Yiling Pharmaceutical Co: Net profit soared 80.33% to ¥1.00 billion despite a 7.82% revenue decline
- Shijiazhuang Yiling Pharmaceutical Sees 2025 Net Profit 1.2-1.3 Billion Yuan
- Net profit rose 277.56% to ¥1.29 billion on 20.24% revenue growth, with robust cash flow
- Shijiazhuang Yiling Pharmaceutical Says Subsidiary's Irbesartan Approved
Follow Shijiazhuang Yiling Pharmaceutical into a list and get an email when it puts out news.
Follow Shijiazhuang Yiling Pharmaceutical